Author: Alâ€Samkari, Hanny; Song, Fei; Van Cott, Elizabeth; Kuter, David J.; Rosovsky, Rachel
Title: Evaluation of the Prothrombin Fragment 1.2 in Patients with COVIDâ€19 Cord-id: abgce27s Document date: 2020_8_11
ID: abgce27s
Snippet: INTRODUCTION: Coronavirus disease 2019 (COVIDâ€19) may cause a hypercoagulable state. The Dâ€dimer is frequently elevated in COVIDâ€19, but other markers of coagulation activation, including the prothrombin fragment 1.2 (PF1.2) are poorly described. METHODS: We studied hospitalized adults with COVIDâ€19 and PF1.2 measurement performed at any time during hospitalization. We evaluated the relationship between PF1.2 and synchronously measured Dâ€dimer. We utilized receiver operating characteri
Document: INTRODUCTION: Coronavirus disease 2019 (COVIDâ€19) may cause a hypercoagulable state. The Dâ€dimer is frequently elevated in COVIDâ€19, but other markers of coagulation activation, including the prothrombin fragment 1.2 (PF1.2) are poorly described. METHODS: We studied hospitalized adults with COVIDâ€19 and PF1.2 measurement performed at any time during hospitalization. We evaluated the relationship between PF1.2 and synchronously measured Dâ€dimer. We utilized receiver operating characteristic (ROC) analysis to evaluate optimal thresholds for diagnosing thrombosis and multivariable logistic regression to evaluate association with thrombosis. RESULTS: 115 patients were included [110 (95.7%) critically ill]. PF1.2 and Dâ€dimer were moderately positively correlated (r=0.542, P<0.001) but significant discordance was observed in elevation of each marker above the laboratory reference range (59.0% elevated PF1.2 vs. 98.5% elevated Dâ€dimer). Median PF1.2 levels were higher in patients with thrombosis than those without (611 vs. 374 pmol/L, P=0.006). In ROC analysis, PF1.2 had superior specificity and conferred a higher positive likelihood ratio in identifying patients with thrombosis than Dâ€dimer (PF1.2 threshold of >523 pmol/L: 69.2% sensitivity, 67.7% specificity; >924 pmol/L: 37.9% sensitivity, 87.8% specificity). In multivariable analysis, a PF1.2 >500 pmol/L was significantly associated with VTE [adjusted odds ratio (OR) 4.26, 95% CI, 1.12â€16.21, P=0.034] and any thrombotic manifestation (adjusted OR 3.85, 95% CI, 1.39â€10.65, P=0.010); conversely, synchronously measured Dâ€dimer was not significantly associated with thrombosis. 90.6% of patients with a nonâ€elevated PF1.2 result did not develop VTE. CONCLUSIONS: PF1.2 may be a useful assay, and potentially more discriminant than Dâ€dimer, in identifying thrombotic manifestations in hospitalized patients with COVIDâ€19. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date